Clinical Trial Update: Study of CTO1681 for the Prevention and Treatment of CRS in DLBCL Patients Receiving CAR T-Cell Therapy [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial update indicates CTO1681 is being studied in Phase 1/2 to prevent or treat cytokine release syndrome in patients with diffuse large B-cell lymp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• CTO1681

Snippet

Sponsor: CytoAgents, Inc. | Conditions: Cytokine Release Syndrome | Phase 1, Phase 2 | Status: RECRUITING